scholarly journals Delta tocotrienol in recurrent ovarian cancer. A phase II trial

2019 ◽  
Vol 141 ◽  
pp. 392-396 ◽  
Author(s):  
Caroline Brenner Thomsen ◽  
Rikke Fredslund Andersen ◽  
Karina Dahl Steffensen ◽  
Parvin Adimi ◽  
Anders Jakobsen
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

2004 ◽  
Vol 54 (4) ◽  
pp. 283-289 ◽  
Author(s):  
Robert J. Morgan ◽  
Timothy W. Synold ◽  
David Gandara ◽  
Franco Muggia ◽  
Sidney Scudder ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Resistant

scholarly journals Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment

2020 ◽  
Vol 159 (1) ◽  
pp. 88-94
Author(s):  
Jung-Min Lee ◽  
Christina M. Annunziata ◽  
John L. Hays ◽  
Liang Cao ◽  
Peter Choyke ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Bevacizumab Treatment

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 5004-5004 ◽  
Author(s):  
R. T. Penson ◽  
C. Whalen ◽  
B. Lasonde ◽  
C. N. Krasner ◽  
P. Konstantinopoulos ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Sensitive

Phase II trial of dose dense (weekly) paclitaxel with pembrolizumab (MK-3475) in platinum-resistant recurrent ovarian cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS5612-TPS5612 ◽  
Author(s):  
Robert Michael Wenham ◽  
Sachin M. Apte ◽  
Mian M. Shahzad ◽  
Jae K Lee ◽  
Denise Dorman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Weekly Paclitaxel ◽  
Platinum Resistant ◽  
Dose Dense

scholarly journals A phase II trial of capecitabine (Xeloda®) in recurrent ovarian cancer

2003 ◽  
Vol 89 (10) ◽  
pp. 1843-1848 ◽  
Author(s):  
P A Vasey ◽  
L McMahon ◽  
J Paul ◽  
N Reed ◽  
S B Kaye
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer

A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy

2013 ◽  
Vol 130 (1) ◽  
pp. 19-24 ◽  
Author(s):  
Robert M. Wenham ◽  
James Lapolla ◽  
Hui-Yi Lin ◽  
Sachin M. Apte ◽  
Johnathan M. Lancaster ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Based Chemotherapy

scholarly journals A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer

2019 ◽  
Vol 26 (5) ◽  
pp. 1009-1016 ◽  
Author(s):  
Amit M. Oza ◽  
Ursula A. Matulonis ◽  
Angeles Alvarez Secord ◽  
John Nemunaitis ◽  
Lynda D. Roman ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Resistant ◽  
Randomized Phase Ii

Doxil and gemcitabine combination therapy for recurrent ovarian cancer: Results of a phase II trial

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 5090-5090 ◽  
Author(s):  
R. W. Holloway ◽  
N. J. Finkler ◽  
L. P. Nye ◽  
G. E. Bigsby ◽  
B. H. Ortiz
Keyword(s):  
Ovarian Cancer ◽  
Combination Therapy ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 5005-5005 ◽  
Author(s):  
M. J. Birrer ◽  
P. Konstantinopoulos ◽  
R. T. Penson ◽  
M. Roche ◽  
A. Ambrosio ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Recurrent Ovarian Cancer ◽  
Platinum Resistant
Sign in / Sign up

Export Citation Format

Share Document